Compass Pathways (NASDAQ:CMPS) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Compass Pathways (NASDAQ:CMPS) from a strong sell rating to a hold rating in a report released on Saturday morning.

A number of other brokerages have also weighed in on CMPS. Maxim Group lifted their price target on shares of Compass Pathways from $12.00 to $20.00 and gave the company a “buy” rating in a research note on Friday. Jefferies Financial Group raised shares of Compass Pathways to a “strong-buy” rating in a research note on Tuesday, May 5th. B. Riley Financial began coverage on shares of Compass Pathways in a research note on Friday, April 24th. They issued a “buy” rating and a $17.00 price target on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Compass Pathways in a research note on Monday, April 20th. Finally, Morgan Stanley lifted their price target on shares of Compass Pathways from $16.00 to $17.00 and gave the company an “overweight” rating in a research note on Thursday. Two research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $20.58.

Compass Pathways Stock Down 2.4%

Shares of NASDAQ CMPS opened at $10.37 on Friday. The stock has a market cap of $1.34 billion, a P/E ratio of -3.29 and a beta of 2.39. The firm has a 50 day moving average price of $7.23 and a 200 day moving average price of $6.74. The company has a debt-to-equity ratio of 0.15, a quick ratio of 0.77 and a current ratio of 3.32. Compass Pathways has a 52-week low of $2.25 and a 52-week high of $11.27.

Compass Pathways (NASDAQ:CMPS) last issued its quarterly earnings data on Wednesday, May 13th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.15. Analysts expect that Compass Pathways will post -0.99 EPS for the current year.

Institutional Trading of Compass Pathways

Institutional investors have recently made changes to their positions in the business. Hennion & Walsh Asset Management Inc. lifted its position in shares of Compass Pathways by 169.0% in the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 424,800 shares of the company’s stock worth $2,931,000 after purchasing an additional 266,908 shares in the last quarter. Jefferies Financial Group Inc. bought a new stake in shares of Compass Pathways in the third quarter worth $7,890,000. Propel Bio Management LLC bought a new stake in shares of Compass Pathways in the third quarter worth $2,922,000. Blue Owl Capital Holdings LP lifted its position in shares of Compass Pathways by 163.1% in the third quarter. Blue Owl Capital Holdings LP now owns 604,914 shares of the company’s stock worth $3,466,000 after purchasing an additional 375,000 shares in the last quarter. Finally, ARK Investment Management LLC lifted its position in shares of Compass Pathways by 28.6% in the third quarter. ARK Investment Management LLC now owns 2,121,118 shares of the company’s stock worth $12,154,000 after purchasing an additional 471,897 shares in the last quarter. Institutional investors own 46.19% of the company’s stock.

Compass Pathways News Roundup

Here are the key news stories impacting Compass Pathways this week:

• Positive Sentiment: HC Wainwright increased its FY2028 EPS estimate for Compass Pathways to $1.64 from $1.56 and reiterated a Buy rating with a $70 price target, implying strong long-term upside expectations.
• Positive Sentiment: HC Wainwright also raised its FY2029 EPS estimate to $3.78 from $3.69, further reinforcing a bullish outlook on future earnings growth.
• Positive Sentiment: HC Wainwright lifted its FY2030 EPS estimate to $6.59 from $6.46, signaling confidence in Compass Pathways’ long-range commercial potential.
• Positive Sentiment: Lifesci Capital raised its FY2026 EPS estimate to a loss of $1.45 from a larger loss of $1.79 and kept a Strong-Buy rating, suggesting near-term losses may be narrowing. Article link
• Neutral Sentiment: Lifesci Capital also nudged up its Q3 2026 and Q4 2026 EPS estimates, but both quarters still call for losses, so the impact is mixed. Article link
• Neutral Sentiment: BTIG Research reiterated its Buy rating on Compass Pathways, while Wall Street Zen upgraded the stock to Hold, adding support but not a fresh catalyst. Article title Article title
• Negative Sentiment: Lifesci Capital trimmed its Q2 2026 EPS estimate to a loss of $0.50 from $0.44, indicating somewhat weaker near-term expectations. Article link

About Compass Pathways

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.